ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 929

Antibiotic Exposure and the Development of Juvenile Idiopathic Arthritis: A Population-Based Case-Control Study

Daniel B. Horton1,2, Frank I. Scott IV1,3, Kevin Haynes1, Mary E. Putt1, Carlos D. Rose2, James D. Lewis1,3 and Brian L. Strom1,4, 1Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Pediatrics, Division of Rheumatology, Nemours A.I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE, 3Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA, 4Rutgers Biomedical and Health Sciences, Newark, NJ

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Antibiotics, Etiopathogenesis, juvenile idiopathic arthritis (JIA) and microbiome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Dysregulation of the human microbiome has been implicated in the development of several autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease (IBD). Moreover, antibiotic exposure has been linked with the development of IBD in children. This study aimed to determine whether early antibiotic exposure increases the risk of incident juvenile idiopathic arthritis (JIA) in a general pediatric population.

Methods: A nested case-control study was conducted using The Health Improvement Network, a United Kingdom population-based medical records database with comprehensive diagnostic and outpatient prescription data. Children with incident JIA diagnosed before age 16 were identified by validated diagnostic codes (positive predictive value 86%). Age- and sex-matched control subjects were randomly selected with incidence density sampling in a 10:1 ratio from general practices taking care of at least 1 child diagnosed with JIA. Eligible subjects needed to be registered within 3 months of their birthdate. Individuals with prior IBD, immunodeficiency, autoimmune connective tissue disease, or vasculitis were excluded. The association between antibiotic prescriptions and JIA diagnosis was determined by conditional logistic regression.

Results: There were 153 children diagnosed with JIA in the study population (table 1). Any antibiotic exposure was associated with an increased risk of developing JIA after adjusting for confounders (adjusted OR 2.6, 95% CI 1.5,4.6) (table 2). This risk increased with the number of prescriptions in a dose-dependent manner. These results did not significantly change when adjusting for the number or type of infections. Age of exposure did not significantly modify this association. The relationship between antibiotics and incident JIA was similar across different antibiotic classes, although use of non-bacterial antimicrobial agents (e.g., antifungal, antiviral) was not associated with JIA. In sensitivity analyses excluding data up to 12 months before the index date, the association between antibiotics and incident JIA did not substantively change.

Conclusion: Antibiotic exposure was associated with an increased incidence of JIA in a dose-dependent fashion in a large pediatric population. This study implicates a role for antibiotic exposure in disease pathogenesis, perhaps mediated through alteration in the microbiome.

 Table 1. Subject characteristics

 Cases

 n = 153

 Controls

 n = 1530

 Total

 n = 1683

 p value

 Female

 96 (63)

 960 (63)

 1056 (63)

 1.00

 Age category

    1-5 years

    6-10 years

    11-15 years

 107 (70)

 36 (23)

 10 (7)

1070 (70)

 360 (23)

 100 (7)

 1177 (70)

 396 (23)

 110 (7)

 1.00

 Low socioeconomic status

 23 (15)

 216 (14)

 239 (14)

 0.65

 Personal autoimmune disease

    Psoriasis

    Type 1 diabetes

    Thyroid disease

    Uveitis

 5 (3)

 3 (2)

 1 (0.7)

 1 (0.7)

 1 (0.7)

 2 (0.1)

 2 (0.1)

 0

 0

 0

 7 (0.4)

 5 (0.3)

 1 (<0.1)

 1 (<0.1)

 1 (<0.1)

 <0.001

 Hospitalization

 44 (29)

 195 (13)

 239 (14)

 <0.001

 Any infection

    Upper respiratory

    Lower respiratory

    Gastrointestinal

    Skin and soft tissue

    Urinary tract

    Bone and joint

    Other

 142 (93)

 125 (82)

 37 (24)

 30 (20)

 35 (23)

 7 (5)

 0

 83 (54)

 1313 (86)

 1138 (74)

 394 (26)

 253 (17)

 296 (19)

 63 (4)

 0

 865 (57)

 1455 (86)

 1263 (75)

 431 (26)

 283 (17)

 331 (20)

 70 (4)

 0

 948 (56)

 0.02

 Total infections, median (IQR)

 3 (1,4)

 2 (1,4)

 2 (1,4)

 <0.001

 Any antibiotic exposure

    Antianaerobic

    Not antianaerobic

 134 (88)

 127 (83)

 65 (42)

 1157 (76)

 1109 (72)

 475 (31)

 1291 (77)

 1236 (73)

 540 (32)

 <0.001

 0.004

 0.002

 Number of antibiotic courses received

    Unexposed

    1-2 courses

    3-5 courses

    More than 5 courses

 19 (12)

 40 (26)

 46 (30)

 48 (31)

 

 373 (24)

 500 (33)

 345 (23)

 312 (20)

 

 392 (23)

 540 (32) 

 391 (23)

 360 (21)

 <0.001

 

 *Other antimicrobial exposure, any

 45 (29)

 405 (26)

 450 (27)

 0.43

 Maternal autoimmune disease

 21 (14)

 116 (8)

 137 (8)

 0.02

 Prenatal antibiotic exposure

 47 (31)

 512 (33)

 559 (33)

 0.51

 Legend. IQR interquartile range. All statistics are expressed as n (%) unless otherwise stated. All p values were obtained from univariable conditional logistic regression models.

 *Other antimicrobial agents, including antifungal, antiviral, and antimycobacterial drugs.

 Table 2. Multivariable models

 Exposure associated with JIA

 Odds ratio

 95% CI

 p value

 Any antibiotic

 2.6

 1.5,4.6

 0.001

 Any antibiotic, by dose category

    Unexposed (reference)

    1-2 courses

    3-5 courses

    More than 5 courses

 

 

 2.0

 3.1

 3.8

 

 

 1.1,3.7

 1.6,5.8

 1.9,7.3

 

 

 0.03

 <0.001

 <0.001

 Legend. Final models adjusted for matching, personal autoimmune

 disease (any), hospitalization, and maternal autoimmune disease (any).



Disclosure:

D. B. Horton,
None;

F. I. Scott IV,
None;

K. Haynes,
None;

M. E. Putt,
None;

C. D. Rose,
None;

J. D. Lewis,
None;

B. L. Strom,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibiotic-exposure-and-the-development-of-juvenile-idiopathic-arthritis-a-population-based-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology